JOURNAL HOME CME HOME THIS MONTH PAST ISSUES ETOC COLLECTIONS AUTHORS REVIEWERS EDITORIAL BOARD FEEDBACK RSS HELP
		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Prielipp, R. C. Articles by Pearl, R. G. Search for Related Content PubMed PubMed Citation Articles by Prielipp, R. C. Articles by Pearl, R. G.

Hemodynamic Profiles of Prostaglandin E₁, Isoproterenol, Prostacyclin, and Nifedipine in Vasoconstrictor Pulmonary Hypertension in Sheep

Received from the Department of Anesthesia, Stanford University Medical Center, Stanford, California.

Abstract

Patients with pulmonary hypertension challenge the anesthesiologist with complex alterations of hemodynamic function. To study the effects of multiple therapeutic interventions, a stable model of pulmonary hypertension in sheep was developed using continuous infusion of the vasoconstrictor U46619, a thromboxane A₂-mimetic. The pulmonary and systemic effects of four pulmonary vasodilators (prostaglandin E₁, isoproterenol, prostacyclin, and nifedipine) were compared at doses producing equivalent reduction in systemic blood pressure. Although all four drugs decreased pulmonary artery pressure and resistance, distinct differences in drug hemodynamic profiles were found. Prostaglandin E₁, and isoproterenol demonstrated the greatest pulmonary specificity, increased cardiac output significantly, and decreased pulmonary vascular resistance. Prostaglandin E₁ produced the largest decrease in pulmonary artery pressure (from 31 ± 1 to 22 ± 2 mm Hg). Isoproterenol markedly increased heart rate (from 119 ± 6 to 182 ± 20 beats/min) and resulted in significant dysrhythmias that necessitated limiting infusion of this drug; isoproterenol did not affect stroke volume. Prostacyclin demonstrated intermediate pulmonary specificity and produced the largest increase in cardiac output (from 1.7 ± 0.2 to 3.1 ± 0.3 L/min). Nifedipine exhibited the least pulmonary specificity and was the least effective agent in decreasing pulmonary artery pressure. In this model different pulmonary vasodilators exerted different hemodynamic effects, suggesting that appropriate drug selection for treatment of pulmonary hypertension should depend on baseline heart rate and rhythm, pulmonary artery pressure, systemic artery pressure, arterial oxygenation, and cardiac output.

Key Words: LUNG, BLOOD FLOW—pulmonary hypertension • HORMONES, PROSTAGLANDINS—prostacyclin • PHARMACOLOGY—nifedipine • HEART—isoproterenol

This article has been cited by other articles:

				M. Igarashi, A. Kita, K. Nishikawa, M. Nakayama, K. Tsunoda, and A. Namiki Use of percutaneous cardiopulmonary support in catastrophic massive pulmonary fat embolism Br. J. Anaesth., February 1, 2006; 96(2): 213 - 215. [Abstract] [Full Text] [PDF]

				C. PUTENSEN, C. HORMANN, A. KLEINSASSER, and G. PUTENSEN-HIMMER Cardiopulmonary Effects of Aerosolized Prostaglandin E1 and Nitric Oxide Inhalation in Patients with Acute Respiratory Distress Syndrome Am. J. Respir. Crit. Care Med., June 1, 1998; 157(6): 1743 - 1747. [Abstract] [Full Text] [PDF]

Anesthesia & Analgesia® is published for the International Anesthesia Research Society® by Lippincott Williams & Wilkins with the assistance of Stanford University Libraries' HighWire Press®. Copyright 2006 by the International Anesthesia Research Society. Online ISSN: 1526-7598   Print ISSN: 0003-2999